

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

QIAGEN SCIENCES, LLC,
Petitioner, v.

TECAN GENOMICS, INC.,
Patent Owner.

IPR2025-00028

IPR2025-00029

U.S. Patents 10,036,012 and 10,876,108

**PETITIONER'S OBJECTIONS TO ADMISSIBILITY OF
SUPPLEMENTAL EVIDENCE SUBMITTED BY PATENT OWNER**

Pursuant to 37 C.F.R. § 42.64(b) and the Federal Rules of Evidence (“FRE”), Petitioner QIAGEN Sciences, LLC (“QIAGEN”), hereby objects as follows to the admissibility of evidence served by Patent Owner Tecan Genomics, Inc. (“Patent Owner”) via email on September 5, 2025. Patent Owner served the below exhibits on QIAGEN stating it was “supplemental evidence” and did not provide any further explanation. The below exhibits are not cited in Patent Owner’s Papers or supporting declarations. Accordingly, QIAGEN cannot ascertain the purpose of these exhibits and reserves the right to make further objections if the purpose of these exhibits is revealed.

Exhibit	Objections
Ex.2181 - QIAseq and Single Primer Extension Chemistry: Redefining Amplicon-Based NGS, QIAGEN (2018)	FRE 802: To the extent it is being offered to prove the truth of the matter asserted, this exhibit constitutes inadmissible hearsay. FRE 401 and 402: The exhibit is not cited in patent owner’s response or any other paper or exhibit and therefore is not relevant to any ground upon which trial was instituted. Exhibits and arguments that are not incorporated in papers are waived and incorporation by reference is strictly prohibited. 37 C.F.R. § 42.6(a)(3); 37 C.F.R. § 42.22; see also <i>Parus Holdings, Inc. v. Google LLC</i> , 70 F.4th 1365, 1371 (Fed. Cir. 2023).

	QIAGEN further objects to the timeliness of this exhibit which was served 16 days after Patent Owner submitted its Patent Owner Response.
Ex.2182 - <i>The Cost of Sequencing a Human Genome</i>, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (last visited February 19, 2025).	FRE 401 and 402: The exhibit is not cited in patent owner's response or any other paper or exhibit and therefore is not relevant to any ground upon which trial was instituted. Exhibits and arguments that are not incorporated in papers are waived and incorporation by reference is strictly prohibited. 37 C.F.R. § 42.6(a)(3); 37 C.F.R. § 42.22; see also <i>Parus Holdings, Inc. v. Google LLC</i>, 70 F.4th 1365, 1371 (Fed. Cir. 2023). FRE 106: The exhibit is incomplete and ought to be considered, in fairness, at the same time as the remainder of the source from which it originates. FRE 401 and 402: The exhibit is not prior art and therefore is not relevant to any question of patentability. FRE 402 and 403: The exhibit is not prior art. Therefore, the exhibit's probative value with respect to any ground upon which trial was instituted is substantially outweighed by the danger of unfair prejudice, confusing the issues, undue delay, wasting time, or needlessly presenting cumulative evidence.

	FRE 802: To the extent it is being offered to prove the truth of the matter asserted, Exhibit 2006 constitutes inadmissible hearsay. FRE 901: Patent Owner has not produced evidence or certification sufficient to support a finding that the exhibit is what Patent Owner claims it is. QIAGEN further objects to the timeliness of this exhibit which was served 16 days after Patent Owner submitted its Patent Owner Response.
--	--

DATED: September 12, 2025

Respectfully submitted,

By /Matthew A. Traupman/

Matthew A. Traupman (Reg. No. 50,832)

matthewtraupman@quinnemanuel.com

QUINN EMANUEL URQUHART

& SULLIVAN LLP

295 Fifth Avenue

New York, NY 10016

Tel: (212) 849-7000

Fax: (212) 849-7100

*Attorneys for Petitioner QIAGEN Sciences,
LLC*

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on September 12, 2025. I caused a true and correct copy of the foregoing PETITIONER'S OBJECTIONS TO ADMISSIBILITY OF EVIDENCE SUBMITTED BY PATENT OWNER to be served on counsel for Patent Owner via email at:

Timothy J. Beavers	tbeavers@goodwinlaw.com
Linnea P. Cipriano	lcipriano@goodwinlaw.com
John P. Padro	jpadro@goodwinlaw.com
Scott T. Weingaertner	sweingaertner@goodwinlaw.com

DATED: September 12, 2025

/Matthew A. Traupman/
Matthew A. Traupman (Reg. No. 50,832)
matthewtraupman@quinnemanuel.com
QUINN EMANUEL URQUHART
& SULLIVAN LLP
295 Fifth Avenue
New York, NY 10016
Tel: (212) 849-7000
Fax: (212) 849-7100

*Attorneys for Petitioner QIAGEN Sciences,
LLC*